DK1082341T3 - Anvendeligt tumorantigen i diagnose og behandling af prostata- og koloncancer - Google Patents

Anvendeligt tumorantigen i diagnose og behandling af prostata- og koloncancer

Info

Publication number
DK1082341T3
DK1082341T3 DK99927164.6T DK99927164T DK1082341T3 DK 1082341 T3 DK1082341 T3 DK 1082341T3 DK 99927164 T DK99927164 T DK 99927164T DK 1082341 T3 DK1082341 T3 DK 1082341T3
Authority
DK
Denmark
Prior art keywords
prostate
tmprss2
diagnosis
colon cancer
treatment
Prior art date
Application number
DK99927164.6T
Other languages
English (en)
Inventor
Daniel E Afar
Rene S Hubert
Kahan Leong
Arthur B Raitano
Douglas C Saffran
Stephen Chappell Mitchell
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Application granted granted Critical
Publication of DK1082341T3 publication Critical patent/DK1082341T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK99927164.6T 1998-06-01 1999-06-01 Anvendeligt tumorantigen i diagnose og behandling af prostata- og koloncancer DK1082341T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8759898P 1998-06-01 1998-06-01
US9147498P 1998-06-29 1998-06-29
US12952199P 1999-04-14 1999-04-14
PCT/US1999/012253 WO1999062942A2 (en) 1998-06-01 1999-06-01 Tumor antigen useful in diagnosis and therapy of prostate and colon cancer

Publications (1)

Publication Number Publication Date
DK1082341T3 true DK1082341T3 (da) 2011-03-28

Family

ID=27375711

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99927164.6T DK1082341T3 (da) 1998-06-01 1999-06-01 Anvendeligt tumorantigen i diagnose og behandling af prostata- og koloncancer

Country Status (12)

Country Link
US (1) US20060275304A1 (da)
EP (1) EP1082341B1 (da)
JP (2) JP2002517185A (da)
AT (1) ATE490977T1 (da)
AU (2) AU773187B2 (da)
CA (1) CA2329137C (da)
CY (1) CY1111906T1 (da)
DE (1) DE69943020D1 (da)
DK (1) DK1082341T3 (da)
IL (1) IL139988A0 (da)
PT (1) PT1082341E (da)
WO (1) WO1999062942A2 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
AU1097500A (en) * 1998-10-02 2000-04-26 Agensys, Inc. Human gene expressed in cancers of prostate, bladder, pancreas and colon, 36p1a6
EP1131095A4 (en) * 1998-10-19 2003-04-23 Diadexus Inc METHOD FOR DIAGNOSING, MONITORING, CLASSIFYING STAGES, VISUALIZING AND TREATING PROSTATE CANCER
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU4484400A (en) * 1999-04-23 2000-11-10 University Of Washington Prostate-specific polynucleotides, polypeptides and their methods of use
DK1992695T3 (da) 1999-08-12 2011-02-14 Agensys Inc Lectin-transmembran-antigen af type C udtrykt i human prostatacancer og avendelser deraf
EP1287029A2 (en) * 2000-06-09 2003-03-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
EP1294903B1 (en) 2000-06-13 2008-05-07 Bayer HealthCare AG Regulation of human transmembrane serine protease
ES2323407T3 (es) * 2000-07-12 2009-07-15 Agensys, Inc. Nuevo antigeno tumoral util en el diagnostico y terapia del cancer de vejiga, ovario, pulmon y riñon.
US6743592B1 (en) * 2000-07-25 2004-06-01 The Trustees Of The University Of Pennsylvania Methods, systems and kits for immuno-detection of epitopes expressed on molecules
US20040018973A1 (en) * 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
WO2004092397A2 (en) * 2003-04-15 2004-10-28 Novartis Ag Tmprss2 regulatory sequences and uses thereof
WO2004097358A2 (en) * 2003-05-02 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
JP5512125B2 (ja) 2005-09-12 2014-06-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
WO2008119767A2 (en) * 2007-03-30 2008-10-09 Oryzon Genomics, S. A. Method of nucleic acid analysis.
JP5433572B2 (ja) 2007-07-06 2014-03-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｉｐｏｌ１−ｅｔｖ１遺伝子再編成
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
WO2011034906A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
ES2676031T3 (es) * 2012-02-15 2018-07-16 F. Hoffmann-La Roche Ag Cromatografía de afinidad basada en el receptor Fc
RU2714116C2 (ru) 2014-11-06 2020-02-11 Ф. Хоффманн-Ля Рош Аг ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМ СВЯЗЫВАНИЕМ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5288612A (en) * 1991-07-03 1994-02-22 The Scripps Research Institute Assay methods for detecting serum proteases, particularly activated protein C
JP3149185B2 (ja) * 1993-01-15 2001-03-26 ジェネティックス・インスティテュート・インコーポレイテッド エンテロキナーゼのクローニングおよび使用方法
EP1630235A3 (en) * 1997-02-25 2009-05-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and method for their use
US6657056B2 (en) * 1997-02-25 2003-12-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6800746B2 (en) * 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
AU731840B2 (en) * 1997-02-25 2001-04-05 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6043033A (en) * 1997-02-27 2000-03-28 Incyte Pharmaceuticals, Inc. Human prostate-associated protease
US20030103981A1 (en) * 1997-02-27 2003-06-05 Incyte Genomics, Inc. Methods of use of a prostate-associated protease in the diagnosis and treatment of prostate cancer
US20020119531A1 (en) * 1997-02-27 2002-08-29 Olga Bandman Prostate-associated protease antibody
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
AU4839999A (en) * 1998-06-29 2000-01-17 Myriad Genetics, Inc. Tmprss2 is a tumor suppressor
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US6331427B1 (en) * 1999-03-26 2001-12-18 Millennium Pharmaceuticals, Inc. Protease homologs
US20020192763A1 (en) * 2000-04-17 2002-12-19 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US20020160382A1 (en) * 2000-10-11 2002-10-31 Lasek Amy W. Genes expressed in colon cancer
US20030065157A1 (en) * 2001-04-04 2003-04-03 Lasek Amy W. Genes expressed in lung cancer

Also Published As

Publication number Publication date
JP2009148265A (ja) 2009-07-09
JP2002517185A (ja) 2002-06-18
AU773187B2 (en) 2004-05-20
CA2329137C (en) 2011-09-20
IL139988A0 (en) 2002-02-10
ATE490977T1 (de) 2010-12-15
AU4413699A (en) 1999-12-20
CY1111906T1 (el) 2015-11-04
US20060275304A1 (en) 2006-12-07
EP1082341A2 (en) 2001-03-14
AU2004202306A1 (en) 2004-06-24
PT1082341E (pt) 2011-02-15
DE69943020D1 (de) 2011-01-20
AU2004202306C1 (en) 2008-05-01
CA2329137A1 (en) 1999-12-09
WO1999062942A2 (en) 1999-12-09
AU2004202306B2 (en) 2007-05-24
WO1999062942A3 (en) 2000-06-02
EP1082341B1 (en) 2010-12-08

Similar Documents

Publication Publication Date Title
CY1111906T1 (el) Αντιγονο ογκων χρησιμο για τη διαγνωση και θεραπεια καρκινου του προστατη και του παχεος εντερου
DE69734109D1 (de) Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung
AU1726199A (en) Metastatic cancer regulated gene
ATE169640T1 (de) Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore
ATE478952T1 (de) 36p6d5: ausgeschiedenes tumorprotein
DK0912738T3 (da) Antigen-bindende-fragmenter der specifikt detekterer cancerceller, nukleotider der koder fragmenterne og anvendelse deraf til profylakse og detektion af cancere
BR0112542A (pt) Composições e métodos papa a terapia e a diagnose de câncer ovariano
ES2182908T3 (es) Nuevos peptidos.
DE59101889D1 (de) Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie.
ATE397062T1 (de) Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
ATE421531T1 (de) Apoptose-bezogene verbindungen und deren verwendung
DK0922223T3 (da) Fremgangsmåde til prognosticering af cancer
CY1109254T1 (el) Νεο αντιγονο ογκου χρησιμο στη διαγνωση και θεραπεια καρκινων της ουροδοχου κυστης, των ωοθηκων, του πνευμονα και του νεφρου
Gallee et al. Characterization of monoclonal antibodies raised against the prostatic cancer cell line PC‐82
Barra et al. Primary structure of human copper-zinc superoxide dismutase. Cysteine-and tryptophan—Containing peptides
NO991653L (no) Immunogenisk tumor frigjorte partikler (TLP)-blanding
ATE449171T1 (de) Reagentia und verfahren zum nachweis von brustkrankheiten
ATE205529T1 (de) Reninaktive substanz enthaltend humanes prorenin und antikörper gegen das prorenin profragment
DE60134956D1 (de) Gene differentiell experimiert in brudtkrebs
FR2795414B1 (fr) Polypeptide icbp90 et ses fragments et polynucleotides codant lesdits polypeptides et applications au diagnostic et au traitement du cancer
DK1399482T3 (da) Bestemmelse af bone-sialoprotein i kropsvæsker til on-kologiske problemstillinger
AU2003222606A1 (en) Diagnosis of carcinoma using raigi polypeptides
Teng et al. Novel Recombinant Fab Fragments of the Tag-72 Monoclonal Antibody CC49 Containing an Integrated Radiometal Binding Site for Radioimmunoguided Surgery for DCIS
HUP0001270A2 (en) Compositions and methods for the treatment and diagnosis of breast cancer